Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: BMcV who wrote (1964)	3/9/1999 10:12:00 AM
From: David Howe	Respond to of 10280

The drop is an overreaction by the public to news that's been out for a few weeks. Another chance for the institutions to buy the individual investor's shares. The WSJ is reporting something that SEPR has been discussing with analysts since February 19th. From the latest Morgan Stanley report dated February 19th. << Sepracor today disclosed the Federal Trade Commission has requested additional information under the Hart Rodino Act pertaining to Sepracor's Prozac isomer licensing agreement with Eli Lilly. We do not anticipate any problems closing the deal and expect all issues to be revolved in the first half of the year. Should the FTC block the collaboration, however, Sepracor remains in the enviable position of having a potent antidepressant, validated by Lilly's intent to license, which it could develop itself or re-license to a separate company, most likely on even more favorable terms. Thus, Sepracor appears immune, even in the unlikely event that the deal is blocked. >> I hope this helps. Dave